Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis

Gene
Linyan ChenXuelei Ma

Abstract

Because of the deep research about tumorigenesis mechanism, the cognition of cancer has been transferred to molecular level from morphology. Previous articles reported a potential connection between circulating cell-free DNA (cfDNA) and prognosis of pancreatic cancer. A total of 18 related articles including 1243 patients were enrolled to access the relationship between cfDNA and prognosis of pancreatic cancer. The hazard ratio (HR) was used to combine the univariate and multivariate results of included studies. Our result performed that the cfDNA had significant prognostic value in predicting OS (HR = 2.41, 95%CI: 1.93-3.02, I2 = 60%) and PFS (HR = 2.47, 95%CI: 1.80-3.40, I2 = 0%) in univariate analysis. The multivariate analyses about OS (HR = 2.57, 95%CI: 1.95-3.38, I2 = 66%) and PFS (HR = 2.31, 95%CI: 1.47-3.64, I2 = 0%) also showed significance. In conclusion, the cfDNA was a significant prognostic factor for OS and PFS in patients with pancreatic cancer. The mutation (Kras, ERBB2-exon17 and KrasG12V), circulating tumor DNA (ctDNA) presence, hypermethylation and higher concentration of cfDNA were both associated with worse survival results in pancreatic cancer.

Citations

Jul 25, 2019·International Journal of Cancer. Journal International Du Cancer·Marin StrijkerHanneke W van Laarhoven
Aug 16, 2019·Cancers·Richard A JacobsonAshiq Masood
Jun 23, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·R VáraljaiA Roesch
Jul 22, 2019·Journal of Personalized Medicine·Matthew LoftPeter Gibbs
Dec 5, 2020·Critical Reviews in Oncology/hematology·Sara GandiniSaverio Caini
Dec 16, 2020·Cancers·Jedrzej J JaworskiShivan Sivakumar
Feb 4, 2021·Annals of Gastroenterological Surgery·Keinosuke IshidoTaiichi Wakiya
Mar 12, 2021·Frontiers in Cell and Developmental Biology·Yan-Yan YanJian-Ye Zhang
Mar 30, 2021·Radiology. Imaging Cancer·Ajaykumar C MoraniSrinivasa R Prasad
Apr 19, 2021·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Kosho AsanoNaoya Kato
Jun 6, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaoji ChenMinetta C Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

© 2022 Meta ULC. All rights reserved